Pre-clinical tumor models of primary brain tumors: Challenges and opportunities

被引:51
作者
Akter, Farhana [1 ,2 ]
Simon, Brennan [1 ,2 ]
de Boer, Nadine Leonie [1 ]
Redjal, Navid [1 ]
Wakimoto, Hiroaki [1 ,2 ,3 ]
Shah, Khalid [1 ,2 ,4 ]
机构
[1] Harvard Med Sch, Ctr Stem Cell Therapeut & Imaging CSTI, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA
[4] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2021年 / 1875卷 / 01期
基金
美国国家卫生研究院;
关键词
Glioma; Glioblastoma; Brain tumor model; Therapeutic development; Neurooncology; CANCER STEM-CELLS; REGULATORY T-CELLS; GENE-EXPRESSION; HUMANIZED MICE; IMMUNE-SYSTEM; MOUSE MODELS; GLIOMA-CELLS; MALIGNANT GLIOMA; XENOGRAFT MODEL; GROWTH-FACTOR;
D O I
10.1016/j.bbcan.2020.188458
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Primary brain tumors are a heterogeneous group of malignancies that originate in cells of the central nervous system. A variety of models tractable for preclinical studies have been developed to recapitulate human brain tumors, allowing us to understand the underlying pathobiology and explore potential treatments. However, many promising therapeutic strategies identified using preclinical models have shown limited efficacy or failed at the clinical trial stage. The inability to develop therapeutic strategies that significantly improve survival rates in patients highlight the compelling need to revisit the design of currently available animal models and explore the use of new models that allow us to bridge the gap between promising preclinical findings and clinical translation. In this review, we discuss current strategies used to model glioblastoma, the most malignant brain tumor in adults and highlight the shortcomings of specific models that must be circumvented for the development of innovative therapeutic strategies.
引用
收藏
页数:10
相关论文
共 132 条
[1]
Ahronian L.G., 2014, Cold Spring Harb Protoc, V2014, P1128, DOI [DOI 10.1101/NDB.LON069831, 10.1101/pdb.top069831, DOI 10.1101/PDB.TOP069831]
[2]
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection [J].
Akbar, Umar ;
Jones, Terreia ;
Winestone, Jon ;
Michael, Madison ;
Shukla, Atul ;
Sun, Yichun ;
Duntsch, Christopher .
JOURNAL OF NEURO-ONCOLOGY, 2009, 94 (02) :203-212
[3]
The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line [J].
Akiyama, Yasuto ;
Nonomura, Chizu ;
Ashizawa, Tadashi ;
Iizuka, Akira ;
Kondou, Ryota ;
Miyata, Haruo ;
Sugino, Takashi ;
Mitsuya, Koichi ;
Hayashi, Nakamasa ;
Nakasu, Yoko ;
Asai, Akira ;
Ito, Mamoru ;
Kiyohara, Yoshio ;
Yamaguchi, Ken .
IMMUNOLOGY LETTERS, 2017, 190 :20-25
[4]
Humanized immune system mouse models: progress, challenges and opportunities [J].
Allen, Todd M. ;
Brehm, Michael A. ;
Bridges, Sandra ;
Ferguson, Stacy ;
Kumar, Priti ;
Mirochnitchenko, Oleg ;
Palucka, Karolina ;
Pelanda, Roberta ;
Sanders-Beer, Brigitte ;
Shultz, Leonard D. ;
Su, Lishan ;
PrabhuDas, Mercy .
NATURE IMMUNOLOGY, 2019, 20 (07) :770-774
[5]
Mutant IDH1 regulates the tumor-associated immune system in gliomas [J].
Amankulor, Nduka M. ;
Kim, Youngmi ;
Arora, Sonali ;
Kargl, Julia ;
Szulzewsky, Frank ;
Hanke, Mark ;
Margineantu, Daciana H. ;
Rao, Aparna ;
Bolouri, Hamid ;
Delrow, Jeff ;
Hockenbery, David ;
Houghton, A. McGarry ;
Holland, Eric C. .
GENES & DEVELOPMENT, 2017, 31 (08) :774-786
[6]
Comparative Molecular Life History of Spontaneous Canine and Human Gliomas [J].
Amin, Samirkumar B. ;
Anderson, Kevin J. ;
Boudreau, C. Elizabeth ;
Martinez-Ledesma, Emmanuel ;
Kocakavuk, Emre ;
Johnson, Kevin C. ;
Barthel, Floris P. ;
Varn, Frederick S. ;
Kassab, Cynthia ;
Ling, Xiaoyang ;
Kim, Hoon ;
Barter, Mary ;
Lau, Ching C. ;
Ngan, Chew Yee ;
Chapman, Margaret ;
Koehler, Jennifer W. ;
Long, James P. ;
Miller, Andrew D. ;
Miller, C. Ryan ;
Porter, Brian F. ;
Rissi, Daniel R. ;
Mazcko, Christina ;
LeBlanc, Amy K. ;
Dickinson, Peter J. ;
Packer, Rebecca A. ;
Taylor, Amanda R. ;
Rossmeisl, John H., Jr. ;
Woolard, Kevin D. ;
Heimberger, Amy B. ;
Levine, Jonathan M. ;
Verhaak, Roel G. W. .
CANCER CELL, 2020, 37 (02) :243-+
[7]
Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro [J].
Anderson, RC ;
Elder, JB ;
Brown, MD ;
Mandigo, CE ;
Parsa, AT ;
Kim, PD ;
Senatus, P ;
Anderson, DE ;
Bruce, JN .
CLINICAL IMMUNOLOGY, 2002, 102 (01) :84-95
[8]
Glioblastoma with Oligodendroglioma Component (GBM-O): Molecular Genetic and Clinical Characteristics [J].
Appin, Christina L. ;
Gao, Jingjing ;
Chisolm, Candace ;
Torian, Mike ;
Alexis, Dianne ;
Vincentelli, Cristina ;
Schniederjan, Matthew J. ;
Hadjipanayis, Costas ;
Olson, Jeffrey J. ;
Hunter, Stephen ;
Hao, Chunhai ;
Brat, Daniel J. .
BRAIN PATHOLOGY, 2013, 23 (04) :454-461
[9]
Treatment options and outcomes for glioblastoma in the elderly patient [J].
Arvold, Nils D. ;
Reardon, David A. .
CLINICAL INTERVENTIONS IN AGING, 2014, 9 :357-367
[10]
Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse [J].
Ashizawa, Tadashi ;
Iizuka, Akira ;
Nonomura, Chizu ;
Kondou, Ryota ;
Maeda, Chie ;
Miyata, Haruo ;
Sugino, Takashi ;
Mitsuya, Koichi ;
Hayashi, Nakamasa ;
Nakasu, Yoko ;
Maruyama, Kouji ;
Yamaguchi, Ken ;
Katano, Ikumi ;
Ito, Mamoru ;
Akiyama, Yasuto .
CLINICAL CANCER RESEARCH, 2017, 23 (01) :149-158